dextromethorphan bupropion
Adjunctive therapy • Brands: Auvelity
Last reviewed: 2026-01-05
General information
- Class: Adjunctive therapy
- Common US brands: Auvelity
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2026-01-05
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Combination antidepressant pairing dextromethorphan (NMDA receptor antagonist and sigma-1 receptor agonist) with bupropion, which inhibits CYP2D6 to increase dextromethorphan exposure; used for major depressive disorder.
Metabolism & Half‑life
- Metabolism: CYP2D6, CYP2B6
- Half‑life: Steady-state mean 22 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- AUVELITY (dextromethorphan and bupropion) extended-release tablets prescribing information — DailyMed (2026)
- Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI) — Journal of Clinical Psychiatry (2022)
- AGNP TDM Consensus — Pharmacopsychiatry (2018)
- APA Clinical Practice Guideline for the Treatment of Depression — American Psychiatric Association (2023)